Global Macular Edema Market is segmented by Age Group (Child, Adult, Senior), By Gender (Male, Female), by Study Phases (Early Phase, Phase 1, Phase 2, Phase 3, Phase 4), by Study Type (Interventional, Observational), by Molecular Type (Recombinant Protein, Small Molecule), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

Market Overview

Global Macular Edema Market Expected to reach a high CAGR of 10.43% By 2029: DataM Intelligence

Macular Edema is a condition in which fluid gathers in the macular and leads to vision impairment and loss of vision in certain conditions.
Advancements in technologies in the development of new drug delivery systems, the introduction of new drug combinations, rise in macular edema patients are the major factors driving the growth of the macular edema market across the globe.
Increasing the diabetic population which in turn could result in macular edema is also one of the factors driving the growth of the market. Stringent regulations across various regions, availability of alternative therapies, and the high cost of the drugs/medication are the major factor restraining the growth of the market.

The macular edema market is segmented by clinical trial analysis, molecular type, and by geography.
By geography, North America has the largest market share in 2017 accounting for more than half of the market value and this is followed by Europe. Emerging markets are witnessing a faster growth in the market with the Asia-Pacific region growing at a faster growth rate.

The global macular edema market is a consolidated market with the top 4 companies accounting for the largest market share. Some of the recent industry developments include
FDA approves Roche’s Lucentis for treatment of diabetic retinopathy in people with diabetic macular edema
Eylea injection recommended for approval for the treatment of visual impairment due to diabetic macular edema in the European Union